| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | AT-406 | CTRPv2 | pan-cancer | AAC | 0.22 | 2e-06 |
| mRNA | BRD-K99006945 | CTRPv2 | pan-cancer | AAC | 0.22 | 1e-05 |
| mRNA | Zibotentan | GDSC1000 | pan-cancer | AAC | -0.12 | 0.0003 |
| mRNA | Imatinib | CTRPv2 | pan-cancer | AAC | 0.11 | 0.002 |
| mRNA | ruxolitinib | CTRPv2 | pan-cancer | AAC | 0.1 | 0.003 |
| mRNA | KIN001-236 | GDSC1000 | pan-cancer | AAC | -0.094 | 0.004 |
| mRNA | FH535 | GDSC1000 | pan-cancer | AAC | 0.095 | 0.005 |
| mRNA | XMD14-99 | GDSC1000 | pan-cancer | AAC | -0.09 | 0.005 |
| mRNA | Doxorubicin | gCSI | pan-cancer | AAC | -0.14 | 0.006 |
| mRNA | AZD7762 | GDSC1000 | pan-cancer | AAC | 0.08 | 0.01 |